Alantolactone ameliorates cancer cachexia-associated muscle atrophy mainly by inhibiting the STAT3 signaling pathway

Carnosol and its analogues attenuate muscle atrophy and fat lipolysis induced by cancer cachexia

(2021) Shanshan Lu et al.   Journal of Cachexia Sarcopenia and Muscle

Alantolactone Suppresses Proliferation and the Inflammatory Response in Human HaCaT Keratinocytes and Ameliorates Imiquimod-Induced Skin Lesions in a Psoriasis-Like Mouse Model

(2021) Wen-Ho Chuo et al.   Life-Basel

Alantolactone mitigates renal injury induced by diabetes via inhibition of high glucose-mediated inflammatory response and macrophage infiltration

(2020) Yu Zhu et al.   IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

Nutrition interventions to treat low muscle mass in cancer

(2020) Carla M. Prado et al.   Journal of Cachexia Sarcopenia and Muscle

Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia

(2020) Surendra K. Shukla et al.   CANCER LETTERS

Alantolactone induces apoptosis in THP‐1 cells through STAT3, survivin inhibition, and intrinsic apoptosis pathway

(2020) Bashir Ahmad et al.   Chemical Biology & Drug Design

Magnolol inhibits myotube atrophy induced by cancer cachexia through myostatin signaling pathway in vitro

(2020) Zhijuan Ge et al.   Journal of Natural Medicines

Phytotherapy for Cachexia: Where Do We Stand?

(2020) Kenny Kuchta et al.   Frontiers in Pharmacology

Cancer Cachexia: Definition, Staging, and Emerging Treatments

(2020) Jun Ni et al.   Cancer Management and Research

IMB0901 inhibits muscle atrophy induced by cancer cachexia through MSTN signaling pathway

(2019) Dong Liu et al.   Skeletal Muscle

Establishment of a mouse model of cancer cachexia with spleen deficiency syndrome and the effects of atractylenolide I

(2019) Wan-li Zhang et al.   ACTA PHARMACOLOGICA SINICA

Characterization of gut microbiota, bile acid metabolism, and cytokines in intrahepatic cholangiocarcinoma

(2019) Xiaodong Jia et al.   HEPATOLOGY

Anti-Neuroinflammatory Effect of Alantolactone through the Suppression of the NF-κB and MAPK Signaling Pathways

(2019) Tan et al.   Cells

Lung cancer-derived extracellular vesicles induced myotube atrophy and adipocyte lipolysis via the extracellular IL-6-mediated STAT3 pathway

(2019) Wenjun Hu et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Plasma concentration of interleukin-6 was upregulated in cancer cachexia patients and was positively correlated with plasma free fatty acid in female patients

(2019) Jun Han et al.   Nutrition & Metabolism

Cancer cachexia: Diagnosis, assessment, and treatment

(2018) Mohammadamin Sadeghi et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Alantolactone suppresses APOC3 expression and alters lipid homeostasis in L02 liver cells

(2018) Meiting Yang et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Cancer-associated cachexia

(2018) Vickie E. Baracos et al.   Nature Reviews Disease Primers

Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision Medicine

(2018) Michael H. Gerber et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Alantolactone sensitizes human pancreatic cancer cells to EGFR inhibitors through the inhibition of STAT3 signaling

(2018) Hailun Zheng et al.   MOLECULAR CARCINOGENESIS

Z-505 hydrochloride, an orally active ghrelin agonist, attenuates the progression of cancer cachexia via anabolic hormones in Colon 26 tumor-bearing mice

(2017) Makoto Yoshimura et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Total sesquiterpene lactones prepared from Inula helenium L. has potentials in prevention and therapy of rheumatoid arthritis

(2017) Shuang Gao et al.   JOURNAL OF ETHNOPHARMACOLOGY

Alantolactone, a natural sesquiterpene lactone, has potent antitumor activity against glioblastoma by targeting IKKβ kinase activity and interrupting NF-κB/COX-2-mediated signaling cascades

(2017) Xun Wang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

TNF-α and cancer cachexia: Molecular insights and clinical implications

(2017) Hetal J. Patel et al.   LIFE SCIENCES

Epigenetic targeting of bromodomain protein BRD4 counteracts cancer cachexia and prolongs survival

(2017) Marco Segatto et al.   Nature Communications

Pyrrolidine Dithiocarbamate (PDTC) Attenuates Cancer Cachexia by Affecting Muscle Atrophy and Fat Lipolysis

(2017) Chunxiao Miao et al.   Frontiers in Pharmacology

Relationships between oxycodone pharmacokinetics, central symptoms, and serum interleukin-6 in cachectic cancer patients

(2016) Hikaru Sato et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma

(2016) A Miller et al.   ONCOGENE

Alantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cells

(2015) Jaemoo Chun et al.   CANCER LETTERS

Inactivating STAT3: bad for tumor, good for muscle

(2015) Rosanna Piccirillo et al.   CELL CYCLE

Inhibition of Stat3 Activation Suppresses Caspase-3 and the Ubiquitin-Proteasome System, Leading to Preservation of Muscle Mass in Cancer Cachexia

(2015) Kleiton Augusto Santos Silva et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A Key Role for Leukemia Inhibitory Factor in C26 Cancer Cachexia

(2015) Danielle N. Seto et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

An Epidemiological Survey of Cachexia in Advanced Cancer Patients and Analysis on Its Diagnostic and Treatment Status

(2015) Lei Sun et al.   NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL

Pancreatic Cancer-Induced Cachexia Is Jak2-Dependent in Mice

(2014) Marine Gilabert et al.   JOURNAL OF CELLULAR PHYSIOLOGY

The genus Inula and their metabolites: From ethnopharmacological to medicinal uses

(2014) Ana M.L. Seca et al.   JOURNAL OF ETHNOPHARMACOLOGY

Distinct Behaviour of Sorafenib in Experimental Cachexia-Inducing Tumours: The Role of STAT3

(2014) Míriam Toledo et al.   PLoS One

Modeling human cancer cachexia in colon 26 tumor-bearing adult mice

(2014) Erin E. Talbert et al.   Journal of Cachexia Sarcopenia and Muscle

Targeting Apoptosis Pathways in Cancer with Alantolactone and Isoalantolactone

(2013) Azhar Rasul et al.   TheScientificWorldJOURNAL

Alantolactone suppresses inducible nitric oxide synthase and cyclooxygenase-2 expression by down-regulating NF-κB, MAPK and AP-1 via the MyD88 signaling pathway in LPS-activated RAW 264.7 cells

(2012) Jaemoo Chun et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Alantolactone Induces Apoptosis in HepG2 Cells through GSH Depletion, Inhibition of STAT3 Activation, and Mitochondrial Dysfunction

(2012) Muhammad Khan et al.   Biomed Research International

IL-6 regulation on skeletal muscle mitochondrial remodeling during cancer cachexia in the ApcMin/+ mouse

(2012) James P White et al.   Skeletal Muscle

Anti-inflammatory therapies in cancer cachexia

(2011) Josep M. Argilés et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Definition and classification of cancer cachexia: an international consensus

(2011) Kenneth Fearon et al.   LANCET ONCOLOGY

Ultrasound-assisted extraction of alantolactone and isoalantolactone from Inula helenium roots

(2010) Antoaneta Trendafilova et al.   Pharmacognosy Magazine

The role of cytokines in cancer cachexia

(2009) Josep M Argilés et al.   Current Opinion in Supportive and Palliative Care